Bellicum Hit With Stock Drop Suit In Texas Over Drug Risks
Bellicum Pharmaceuticals of Houston has been accused in a proposed class action of failing to disclose potential dangers of one of its clinical immunotherapy drugs, resulting in a 25.8 percent stock...To view the full article, register now.
Already a subscriber? Click here to view full article